Cowen & Co. analyst Boris Peaker maintained a Buy rating on MacroGenics (MGNX) today. The company’s shares closed yesterday at $14.39.
According to TipRanks.com, Peaker is a 3-star analyst with an average return of 2.3% and a 39.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MacroGenics with a $28.40 average price target, representing a 97.4% upside. In a report issued on July 18, H.C. Wainwright also maintained a Buy rating on the stock with a $39 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.39 and a one-year low of $9.87. Currently, MacroGenics has an average volume of 781.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2.
